{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+regimen&page=62",
    "query": {
      "intervention": "Control regimen",
      "page": 62
    },
    "page_size": 10
  },
  "pagination": {
    "page": 62,
    "page_size": 10,
    "total_count": 1569,
    "total_pages": 157,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+regimen&page=63&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+regimen&page=61&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T02:18:22.567Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01571960",
      "title": "Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GEO-D03 DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA/HIV62B (MVA62B) vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for GEO-D03 DNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for MVA62B:",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2012-04",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-11-11T02:18:22.567Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01571960"
    },
    {
      "nct_id": "NCT04079010",
      "title": "The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Blood Flow Restriction",
        "Growth Hormone",
        "Strength Outcomes",
        "Arginine"
      ],
      "interventions": [
        {
          "name": "BFR",
          "type": "PROCEDURE"
        },
        {
          "name": "Arginine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Pill",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Mary Hardin-Baylor",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "25 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 25 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2019-09-04",
      "completion_date": "2019-11-25",
      "has_results": false,
      "last_update_posted_date": "2020-04-02",
      "last_synced_at": "2026-11-11T02:18:22.567Z",
      "location_count": 1,
      "location_summary": "Belton, Texas",
      "locations": [
        {
          "city": "Belton",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04079010"
    },
    {
      "nct_id": "NCT02997189",
      "title": "Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cisplatin Induced Hearing Loss"
      ],
      "interventions": [
        {
          "name": "OTO-104",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otonomy, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-11-15",
      "completion_date": "2017-09-26",
      "has_results": false,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-11-11T02:18:22.567Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02997189"
    },
    {
      "nct_id": "NCT07209267",
      "title": "Baricitinib Curative Repression of HIV-1",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infection",
        "HIV"
      ],
      "interventions": [
        {
          "name": "Antiretroviral Therapy (ART)",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib (LY3009104) 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib (LY3009104) 4 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 35,
      "start_date": "2026-10",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-11-11T02:18:22.567Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07209267"
    },
    {
      "nct_id": "NCT07037420",
      "title": "ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acromegaly"
      ],
      "interventions": [
        {
          "name": "ALXN2420",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 8,
      "start_date": "2025-10-28",
      "completion_date": "2026-06-24",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-11-11T02:18:22.567Z",
      "location_count": 2,
      "location_summary": "Torrance, California • Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07037420"
    },
    {
      "nct_id": "NCT02481219",
      "title": "Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colorectal Cancer Screening"
      ],
      "interventions": [
        {
          "name": "PillCam® COLON 2 procedure-CONTROL",
          "type": "DEVICE"
        },
        {
          "name": "Senna tablets",
          "type": "DRUG"
        },
        {
          "name": "PEG",
          "type": "DRUG"
        },
        {
          "name": "Metoclopramide",
          "type": "DRUG"
        },
        {
          "name": "Erythromycin",
          "type": "DRUG"
        },
        {
          "name": "SUPREP oral sulfate solution",
          "type": "DRUG"
        },
        {
          "name": "Bisacodyl",
          "type": "DRUG"
        },
        {
          "name": "SUPREP oral sulfate solution with Gastrografin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Medtronic - MITG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 122,
      "start_date": "2015-05",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-11-11T02:18:22.567Z",
      "location_count": 6,
      "location_summary": "Anniston, Alabama • Indianapolis, Indiana • Dayton, Ohio + 2 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Dayton",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02481219"
    },
    {
      "nct_id": "NCT04469530",
      "title": "Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 55,
      "start_date": "2020-09-16",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-11-11T02:18:22.567Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04469530"
    },
    {
      "nct_id": "NCT04480086",
      "title": "Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelofibrosis (MF)"
      ],
      "interventions": [
        {
          "name": "Mivebresib",
          "type": "DRUG"
        },
        {
          "name": "Navitoclax",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-03-17",
      "completion_date": "2023-07-28",
      "has_results": false,
      "last_update_posted_date": "2023-08-29",
      "last_synced_at": "2026-11-11T02:18:22.567Z",
      "location_count": 4,
      "location_summary": "Stony Brook, New York • Cincinnati, Ohio • Knoxville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04480086"
    },
    {
      "nct_id": "NCT06329388",
      "title": "Evaluating the Effects of an Oral Protein Supplement on Children's Growth Patterns",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Growth Disorders",
        "Dietary Exposure",
        "Child Development",
        "Bone Development Abnormal",
        "Body Weight",
        "Child Malnutrition"
      ],
      "interventions": [
        {
          "name": "TruHeight Growth Protein Shake",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "TruHeight Vitamins",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Years to 17 Years"
      },
      "enrollment_count": 32,
      "start_date": "2023-01-18",
      "completion_date": "2023-08-11",
      "has_results": false,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-11-11T02:18:22.567Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06329388"
    },
    {
      "nct_id": "NCT00153062",
      "title": "PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Aggrenox",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel placebo",
          "type": "DRUG"
        },
        {
          "name": "Micardis",
          "type": "DRUG"
        },
        {
          "name": "Aggrenox placebo",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Micardis placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 20332,
      "start_date": "2003-08",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-05-13",
      "last_synced_at": "2026-11-11T02:18:22.567Z",
      "location_count": 204,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 160 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Northport",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00153062"
    }
  ]
}